Sagimet Biosciences Inc (SGMT)

NASDAQHealth CareBiotechnologySnapshot 2026-11-05

$9.12-8.71%

Close 2026-11-05 · 1-day change

Sagimet Biosciences Inc (SGMT) Outlook: What's Priced In | QuarterlyIQ

Investment OutlookAs of Nov 5, 2026

What could strengthen or challenge Sagimet Biosciences Inc’s outlook?

The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.

Higher potential upsideImproving expectations

Next-FY EPS estimate change · 30 days

Comparable estimates unavailable

+10% or more+5%0%−5%−10% or less

Matching fiscal periods, usable estimates and at least one analyst are required.

Higher risk of downsideWeakening expectations

One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.

How this is measured

The calculation requires same-period, same-provider snapshots, positive EPS, at least one analyst and a baseline within three days of the requested lookback.

Price, analyst earnings & P/E reference

The EPS and P/E reference is not available for SGMT yet.

Measure / period	Management expectations	Analyst expectations

Management figures unavailable.

Current consensus figures unavailable.

What the Thesis Depends On

Three published thesis conditions, with dated milestones shown separately.

Key Factor	Why It Matters	Current Status	Break Condition	Latest Evidence
Limit EPS losses to consensus estimates	A primary condition in Sagimet Biosciences Inc's published investment case. The stated target is EPS no worse than -$1.31 in FY27.	Improving	EPS falls below -$1.31 in FY27	Diluted EPS: $-0.26 per share FY2026-Q2; GAAP. Published target: EPS no worse than -$1.31 in FY27. Annual target cannot be compared with a quarterly or TTM observation. Aug 11, 2026-0.26 USD/share · source valueLast status assessment Nov 5, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.

Incoming Evidence

Compare these dated observations with the operating requirements above

Expectations trend

Same fiscal period

FY2027 · fiscal year ending 2027-12-31 · fmp

FY2027 EPS$-1.34

Outlook in Brief

The evidence, the remaining questions, and what comes next

What's improving

No recovery evidence is reported in the available driver assessments.

Still unresolved / key risks

Limit EPS losses to consensus estimatesDiluted EPS: $-0.26 per share
Advance denifanstat into and through Phase 3 trialDirect metric needs a verified mapping
Generate initial revenue from drug sales or partnershipsRevenue: $0

Next proof point

Nov 12, 2026

Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.

Historical risk context

Observed price history; separate from operating scenarios

Price sensitivity

2.4%Typical daily move · historical

Downside history

-48.4%Maximum drawdown · trailing year

Read detailed Outlook Company context, assumptions & risks

Sagimet Biosciences Inc outlook in detail

The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.

Updated Oct 31, 2026

What kind of bet this is

This is a speculative clinical-stage biotechnology business, not an established earnings compounder. The long-term thesis is in a watch state: management has made progress on trial plans and financing, while recent financial performance remains weak and confidence in the assessment is low.

What's priced into Sagimet Biosciences Inc

The evidence does not provide a valuation level or specific market expectations, so whether SGMT is cheap or expensive versus peers cannot be assessed. No priced-in fragility signals were detected, but that does not resolve the uncertainty around a loss-making business.

What the fundamentals likely do

Near term, results may remain weak while the company advances its clinical programs; the evidence gives no earnings outlook. The first patient entered the denifanstat Phase 3 acne trial in October, and the company reports funding through mid-2029, while TVB-3567’s Phase 2 trial is still expected rather than underway. Execution has been mixed, and a guidance cut is a stated risk.

What Sagimet Biosciences Inc hinges on

Over the multi-year view, the thesis depends on clinical progress, including the denifanstat Phase 3 program and the start of TVB-3567’s Phase 2 trial, as well as maintaining funding through the planned readout. Near term, a guidance cut or weaker employment data could weigh on the outlook; continued strength among healthcare bellwethers could support the sector backdrop.

Bottom line

SGMT’s multi-year view has concrete trial and financing milestones, but remains uncertain because the company is loss-making, recent performance is weak, and clinical execution still matters. Not investment advice.

Development preview · refreshed Nov 6, 2026Open Living FV detail

Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.

Exact estimates & source dates

One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.

FY2027 estimate observations · fmp
Snapshot	EPS	Revenue	EPS / revenue analysts
2026-07-24	$-1.25	$7,526,500	7 / 6
2026-07-25	$-1.25	$7,526,500	7 / 6
2026-07-26	$-1.25	$7,526,500	7 / 6
2026-07-27	$-1.25	$7,526,500	7 / 6
2026-07-28	$-1.25	$7,526,500	7 / 6
2026-07-29	$-1.25	$7,526,500	7 / 6
2026-07-30	$-1.25	$7,526,500	7 / 6
2026-07-31	$-1.31	$7,807,220	9 / 9
2026-08-01	$-1.25	$7,526,500	7 / 6
2026-08-02	$-1.31	$7,807,220	9 / 9
2026-08-03	$-1.25	$7,526,500	7 / 6
2026-08-04	$-1.31	$7,807,220	9 / 9
2026-08-05	$-1.25	$7,526,500	7 / 6
2026-08-06	$-1.31	$7,807,220	9 / 9
2026-08-08	$-1.31	$7,807,220	9 / 9
2026-08-09	$-1.25	$7,526,500	7 / 6
2026-08-10	$-1.31	$7,807,220	9 / 9
2026-08-12	$-1.25	$7,526,500	7 / 6
2026-08-13	$-1.25	$7,526,500	7 / 6
2026-08-14	$-1.25	$7,526,500	7 / 6
2026-08-15	$-1.25	$7,526,500	7 / 6
2026-08-16	$-1.25	$7,526,500	7 / 6
2026-08-17	$-1.25	$7,526,500	7 / 6
2026-08-18	$-1.25	$7,526,500	7 / 6
2026-08-19	$-1.25	$7,526,500	7 / 6
2026-08-20	$-1.38	$7,526,500	7 / 6
2026-08-21	$-1.36	$7,526,500	7 / 6
2026-08-22	$-1.36	$7,526,500	7 / 6
2026-08-23	$-1.36	$7,526,500	7 / 6
2026-08-24	$-1.36	$7,526,500	7 / 6
2026-08-25	$-1.36	$7,526,500	7 / 6
2026-08-26	$-1.39	$7,526,500	7 / 6
2026-08-27	$-1.39	$7,526,500	7 / 6
2026-08-28	$-1.39	$7,526,500	7 / 6
2026-08-29	$-1.39	$7,526,500	7 / 6
2026-08-30	$-1.39	$7,526,500	7 / 6
2026-08-31	$-1.39	$7,526,500	7 / 6
2026-09-01	$-1.39	$7,526,500	7 / 6
2026-09-02	$-1.39	$7,526,500	7 / 6
2026-09-03	$-1.39	$7,526,500	7 / 6
2026-09-04	$-1.39	$7,526,500	7 / 6
2026-09-05	$-1.39	$7,526,500	7 / 6
2026-09-06	$-1.39	$7,526,500	7 / 6
2026-09-07	$-1.39	$7,526,500	7 / 6
2026-09-08	$-1.39	$7,526,500	7 / 6
2026-09-09	$-1.39	$7,526,500	7 / 6
2026-09-10	$-1.41	$7,328,618	7 / 6
2026-09-11	$-1.41	$7,328,618	7 / 6
2026-09-12	$-1.41	$7,328,618	8 / 7
2026-09-13	$-1.41	$7,328,618	8 / 7
2026-09-14	$-1.41	$7,328,618	8 / 7
2026-09-15	$-1.41	$7,328,618	8 / 7
2026-09-16	$-1.41	$7,328,618	8 / 7
2026-09-17	$-1.41	$7,328,618	8 / 7
2026-09-18	$-1.41	$7,328,618	8 / 7
2026-09-19	$-1.41	$7,328,618	8 / 7
2026-09-20	$-1.41	$7,328,618	8 / 7
2026-09-21	$-1.41	$7,328,618	8 / 7
2026-09-22	$-1.41	$7,328,618	8 / 7
2026-09-23	$-1.41	$7,328,618	8 / 7
2026-09-24	$-1.41	$7,328,618	8 / 7
2026-09-25	$-1.42	$7,175,233	8 / 7
2026-09-26	$-1.42	$7,175,233	8 / 7
2026-09-27	$-1.42	$7,175,233	8 / 7
2026-09-28	$-1.42	$7,175,233	8 / 7
2026-09-29	$-1.42	$7,175,233	8 / 7
2026-09-30	$-1.42	$7,175,233	8 / 7
2026-10-01	$-1.42	$7,175,233	8 / 7
2026-10-02	$-1.38	$8,132,332	8 / 7
2026-10-03	$-1.36	$8,132,332	8 / 7
2026-10-04	$-1.36	$8,132,332	8 / 7
2026-10-05	$-1.36	$8,132,332	8 / 7
2026-10-06	$-1.34	$8,132,332	8 / 7
2026-10-07	$-1.34	$8,132,332	8 / 7
2026-10-08	$-1.34	$8,132,332	8 / 7
2026-10-09	$-1.34	$8,132,332	8 / 7
2026-10-10	$-1.34	$8,132,332	8 / 7
2026-10-11	$-1.34	$8,132,332	8 / 7
2026-10-12	$-1.34	$8,132,332	8 / 7
2026-10-13	$-1.34	$8,132,332	8 / 7
2026-10-14	$-1.34	$8,132,332	8 / 7
2026-10-15	$-1.34	$8,132,332	8 / 7
2026-10-16	$-1.34	$8,132,332	8 / 7
2026-10-17	$-1.34	$8,132,332	8 / 7
2026-10-18	$-1.34	$8,132,332	8 / 7
2026-10-19	$-1.34	$8,132,332	8 / 7
2026-10-20	$-1.34	$8,132,332	8 / 7
2026-10-21	$-1.34	$8,132,332	8 / 7
2026-10-22	$-1.34	$8,132,332	8 / 7
2026-10-23	$-1.34	$8,132,332	8 / 7
2026-10-24	$-1.34	$8,132,332	8 / 7
2026-10-25	$-1.34	$8,132,332	8 / 7
2026-10-26	$-1.34	$8,132,332	8 / 7
2026-10-27	$-1.34	$8,132,332	8 / 7
2026-10-28	$-1.34	$8,132,332	8 / 7
2026-10-29	$-1.34	$8,132,332	8 / 7
2026-10-30	$-1.34	$8,132,332	8 / 7
2026-10-31	$-1.34	$8,132,332	8 / 7
2026-11-01	$-1.34	$8,132,332	8 / 7
2026-11-02	$-1.34	$8,132,332	8 / 7
2026-11-03	$-1.34	$8,132,332	8 / 7
2026-11-04	$-1.34	$8,132,332	8 / 7
2026-11-05	$-1.34	$8,132,332	8 / 7

Analyst view

Monthly observations

Buy / Strong BuyHoldSell / Strong Sell

Exact monthly counts

Monthly rating snapshots · fmp. Missing snapshots are not zero.
Date	Buy*	Hold	Sell*
2026-06-01	9	1	0
2026-07-01	9	1	0
2026-08-01	9	1	0
2026-09-01	11	1	1
2026-10-01	11	0	1
2026-11-01	11	0	1

*Buy includes Strong Buy; Sell includes Strong Sell. Monthly counts describe the analyst mix, not the firms behind each recent action.

Latest: 11 Buy / Strong Buy · 0 Hold · 1 Sell / Strong Sell

0 upgrades0 downgrades0 maintains

Recent actions · Oct 7–Nov 5 · 0 recorded

What could strengthen or challenge Sagimet Biosciences Inc’s outlook?

Price, analyst earnings & P/E reference

What the Thesis Depends On

Incoming Evidence

Expectations trend

Outlook in Brief

What's improving

Still unresolved / key risks

Next proof point

Historical risk context

Sagimet Biosciences Inc outlook in detail

What kind of bet this is

What's priced into Sagimet Biosciences Inc

What the fundamentals likely do

What Sagimet Biosciences Inc hinges on

Bottom line

Analyst view

Price-target changes

Bottom line